FDA Chief Marty Makary Signals Sweeping Changes for GLP-1 Drugs and Vaccine Policy

FDA Commissioner Marty Makary has outlined a series of significant regulatory shifts, focusing on the oversight of compounded versions of GLP-1 weight-loss medications. The agency is currently navigating a period of intense internal restructuring, characterized by substantial budget reductions and staff cuts. Makary also indicated that major changes are forthcoming regarding vaccine policies and the agency's strategic approach toward China. While stricter regulation of compounded drugs could benefit major pharmaceutical firms like Eli Lilly and Novo Nordisk, the broader healthcare sector faces uncertainty. The potential for slower drug approval processes due to resource constraints remains a key concern for investors. These developments suggest a transformative era for the FDA under its new leadership.